GeneThera (GeneThera) ROCE % : 0.00% (As of Sep. 2022)

View and export this data going back to 2000. Start your Free Trial

What is GeneThera ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GeneThera's annualized ROCE % for the quarter that ended in Sep. 2022 was 0.00%.

GeneThera ROCE % Historical Data

The historical data trend for GeneThera's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera ROCE % Chart

GeneThera Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

Get a 7-Day Free Trial

GeneThera Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

GeneThera ROCE % Calculation

GeneThera's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-1.009	/	( ( (0.012 - 7.692)	+	(0.006 - 8.179) )	/ 2 )
	=	-1.009	/	( (-7.68	+	-8.173)	/ 2 )
	=	-1.009	/	-7.9265
	=	12.73 %

GeneThera's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	-0.5	/	( ( (0.003 - 8.419)	+	(0.001 - 8.543) )	/ 2 )
	=	-0.5	/	( ( -8.416	+	-8.542 )	/ 2 )
	=	-0.5	/	-8.479
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

GeneThera (OTCPK:GTHR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GeneThera ROCE % Related Terms

Thank you for viewing the detailed overview of GeneThera's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneThera (GeneThera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035

Website

http://genetherainc.com

GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.

Executives

Avel Kolesnikov	director	11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr	10 percent owner	632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd	10 percent owner	CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner	director, officer: Chief Financial Officer	728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici	director, 10 percent owner, officer: Chief Executive Officer	3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry	director, 10 percent owner, officer: Chief Administative Officer	11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines